BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately ...

(Reuters) -The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA has cleared Fujirebio Diagnostics' Lumipulse blood test, marking the first of its kind for Alzheimer's diagnosis.

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

(Bloomberg) -- US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find and treat patients with the mind-robbing disease that affects ...